BetterLife Pharma Files 6-K, Attaches Material Change Report
Ticker: BETRF · Form: 6-K · Filed: Jan 2, 2024 · CIK: 1464165
| Field | Detail |
|---|---|
| Company | Betterlife Pharma INC. (BETRF) |
| Form Type | 6-K |
| Filed Date | Jan 2, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: material-change, foreign-issuer, corporate-filing
TL;DR
**BetterLife Pharma just filed a 6-K with a Material Change Report, so check Exhibit 99.1 for the big news!**
AI Summary
BetterLife Pharma Inc. filed a Form 6-K on January 2, 2024, for the month of December 2023, indicating it is a foreign private issuer. This filing primarily serves to attach a Material Change Report dated January 2, 2024, as Exhibit 99.1. For investors, this means BetterLife Pharma is updating the market on a significant event, and understanding the details of the Material Change Report is crucial for assessing potential impacts on the company's operations or stock value.
Why It Matters
This filing signals that BetterLife Pharma Inc. has experienced a significant event requiring disclosure, which could impact its financial health or future prospects.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the 'Material Change Report' it references could contain information that significantly alters the company's risk profile, making it a medium risk until the report's contents are known.
Analyst Insight
An investor should immediately locate and review the 'Material Change Report' (Exhibit 99.1) referenced in this 6-K to understand the specific event and its potential implications for BetterLife Pharma Inc.'s stock.
Key Players & Entities
- BetterLife Pharma Inc. (company) — the registrant filing the 6-K
- December 2023 (date) — the month for which the report is filed
- January 2, 2024 (date) — the filing date of the 6-K and the Material Change Report
- 333-161157 (other) — Commission File Number
FAQ
What is the primary purpose of this 6-K filing by BetterLife Pharma Inc.?
The primary purpose of this 6-K filing is to furnish a 'Material Change Report' dated January 2, 2024, as Exhibit 99.1, indicating a significant event has occurred that the company needs to disclose.
What is BetterLife Pharma Inc.'s Commission File Number?
BetterLife Pharma Inc.'s Commission File Number is 333-161157, as stated in the filing.
When was this 6-K filing submitted to the SEC?
This 6-K filing was submitted to the SEC on January 2, 2024, as indicated by the 'FILED AS OF DATE' and the date of the Material Change Report.
Is BetterLife Pharma Inc. a domestic or foreign private issuer?
BetterLife Pharma Inc. is a foreign private issuer, as indicated by the 'REPORT OF FOREIGN PRIVATE ISSUER' title and the checkmark for Form 20-F.
What is the business address of BetterLife Pharma Inc.?
The business address of BetterLife Pharma Inc. is 1275 WEST 6TH AVENUE, #300, VANCOUVER, BC V6H 1A6, as listed in the filing.
Filing Stats: 343 words · 1 min read · ~1 pages · Grade level 14.9 · Accepted 2024-01-02 13:37:59
Filing Documents
- betrf_6k.htm (6-K) — 8KB
- betrf_ex991.htm (EX-99.1) — 21KB
- betrf_ex991img2.jpg (GRAPHIC) — 4KB
- 0001477932-24-000006.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 , the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BETTERLIFE PHARMA INC. Date: January 2, 2024 By /s/ Moira Ong Name: Moira Ong Title: Chief Financial Officer 3